Genomics

Dataset Information

0

Soluble adenylyl cyclase induces type 17 inflammation and is a potential therapeutic target in psoriasis


ABSTRACT: Cyclic AMP (cAMP) has a key role in psoriasis pathogenesis, as indicated by the therapeutic efficacy of phosphodiesterase inhibitors that prevent the degradation of cAMP. However, whether soluble adenylate cyclase (sAC) (encoded by the ADCY10 gene), which is an important source for cAMP, is involved in Th17 cell-mediated inflammation or could be an alternative therapeutic target in psoriasis is unknown. We have utilized the imiquimod model of murine psoriasiform dermatitis to address this question. Adcy10-/- mice had reduced erythema, scaling and swelling in the skin and Th17 cell numbers in the draining lymph nodes, compared with wild-type mice after induction of psoriasiform dermatitis with imiquimod. During Th17 polarization in vitro, naïve T cells from Adcy10-/- mice were unable to differentiate to Th17 cells and RNA-seq analysis revealed that sAC was also essential for Th17 cell activation. Interestingly, sAC did not impact Th17 lineage-defining transcription factors (such as RORc and cMAF) but rather was required for CREB-dependent gene expression. Finally, topical application of small molecule sAC inhibitors (sACi) reduced imiquimod-induced psoriasiform dermatitis and IL17 gene expression in the skin. Collectively, these findings demonstrate that sAC is a key factor for inducing type 17 inflammation in the skin and sACi could provide an alternative class of topical therapeutics for psoriasis.

ORGANISM(S): Mus musculus

PROVIDER: GSE175470 | GEO | 2021/10/01

REPOSITORIES: GEO

Similar Datasets

| E-GEOD-78057 | biostudies-arrayexpress
2016-02-19 | GSE78057 | GEO
2021-08-22 | GSE175473 | GEO
2021-08-22 | GSE175471 | GEO
2019-02-15 | GSE110658 | GEO
2015-10-12 | GSE65309 | GEO
2019-06-30 | GSE68750 | GEO
2017-10-06 | GSE104603 | GEO
2017-03-23 | GSE86315 | GEO
2022-12-27 | GSE214836 | GEO